(NASDAQ: ROIV) Roivant Sciences's forecast annual revenue growth rate of 222.98% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 101.87%, and it is also forecast to beat the US market's average forecast revenue growth rate of 25.74%.
Roivant Sciences's revenue in 2025 is $20,329,000.On average, 12 Wall Street analysts forecast ROIV's revenue for 2026 to be $14,224,194,510, with the lowest ROIV revenue forecast at $6,134,236,044, and the highest ROIV revenue forecast at $24,829,050,656. On average, 12 Wall Street analysts forecast ROIV's revenue for 2027 to be $67,841,034,094, with the lowest ROIV revenue forecast at $12,541,104,802, and the highest ROIV revenue forecast at $178,351,869,751.
In 2028, ROIV is forecast to generate $570,984,706,083 in revenue, with the lowest revenue forecast at $329,496,107,522 and the highest revenue forecast at $850,586,245,145.